Tag archive
A crowded rare disease drug pipeline limits new drug differentiation, pushing biotechs and investors to re-assess risk, value creation, and portfolio strategy.
A 4% drop in rare disease diagnosis time in just three years shows the power of UTA’s data‑center model. See how PhD students gain real‑world data, faster labs,
The New Montana Right‑to‑Try Framework In early 2024 the Montana Department of Health and Human...
Over 800 rare disorders slip through the cracks, costing families billions each year. Discover how data tools add hidden fees and what can be done to lower the
A single AI pipeline cut rare disease diagnosis from months to weeks. Discover the data center behind that speed boost and why clinicians are adopting it now.